Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.
Risk & Volatility
Lucid Diagnostics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Profitability
This table compares Lucid Diagnostics and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Rigel Pharmaceuticals | 106.59% | 14.89% | 11.99% |
Analyst Recommendations
This is a breakdown of recent ratings for Lucid Diagnostics and Rigel Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Rigel Pharmaceuticals | 1 | 2 | 3 | 0 | 2.33 |
Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 946.88%. Rigel Pharmaceuticals has a consensus target price of $66.75, indicating a potential upside of 52.02%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Rigel Pharmaceuticals.
Valuation & Earnings
This table compares Lucid Diagnostics and Rigel Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 17.26 | -$58.01 million | ($0.47) | -0.85 |
| Rigel Pharmaceuticals | $294.28 million | 2.81 | $367.02 million | $15.51 | 2.83 |
Rigel Pharmaceuticals has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Rigel Pharmaceuticals beats Lucid Diagnostics on 8 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD). Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
